Abstract:Abstract Background The introduction of anti-PD-1 antibody has greatly improved the clinical outcomes of patients with non-small cell lung cancer(NSCLC). Here we retrospectively analyzed the efficacy of PD-1 antibody-based therapy in patients with locally advanced un-operable or metastatic NSCLC patients and report an association between peripheral blood biomarkers with clinical response in these patients. Methods We conducted a single-center study by including medical record data for NSCLC patients treated with PD-1 antibody first-line or posterior-line either as monotherapy or in combination with chemotherapy. The patients enrolled from 2020 to 2022. Dynamic evaluation of multiple Th1 and Th2 cytokines in the blood serum, as well as analysis of the phenotype of T cells from peripheral blood, was conducted to explore the correlation between cytokines levels, T cell phenotype, and clinical response. Results 88 stage IIIA-IV NSCLC patients were enrolled. 60(68.18%) patients achieved partial response(PR), 13 (14.77%) patients were stable(SD) and 15(17.05%) patients had progressed disease (PD). The disease control rate (DCR) was 82.95%. Our results suggested a significant reduction (P = 0.002, P < 0.005) of lymphocyte absolute counts after treatment in the patients with disease progression(PD). Higher levels of IFN-γ(P = 0.023,P < 0.05), TNF-α(P = 0.00098,P < 0.005 ), IL-4 (P = 0.0031 ,P < .0.005), IL-5 (P = 0.0015,P < 0.005) and IL-10 ( P = 0.036 ,P < 0.05) were detected in peripheral blood prior to the treatment in PR group comparing with PD group.. Besides, those patients with high IL-5、IL-13、IL-4、IL-6、IFN-γ and TNF-α(> 10ng/ml) had superior PFS than those with low IL-5、IL-13、 IL-4、IL-6、IFN-γ and TNF-α(< 10ng/ml). Moreover, the expression of PD-1 expression on CD8 + Tcells was positive associated with the clinical response between response patients (PR)and non-response(SD + PD)patients(P = 0.042, P < 0.05). Conclusions The findings of this study imply that the decrease in absolute blood lymphocyte counts after treatment is correlated to the progression of the disease. It is possible that serum cytokine concentrations can forecast the effectiveness and survival rate of anti-PD-1 blockade therapy in NSCLC patients. In addition, the expression of PD-1 expression on CD8 + Tcells was positive associated with the better clinical response as well. The findings of our study indicated the potential of peripheral blood biomarkers analysis to offer predictive value of PD-1-targeted treatments to NSCLC patients. Large prospective studies need to further clarify the value of these biomarkers.

TCF-1+ PD-1+ CD8+T Cells Are Associated with the Response to PD-1 Blockade in Non-Small Cell Lung Cancer Patients

CD57+CD8+T Cells and Response to PD-1/PD-L1 Blockade in Patients with NSCLC

CD57-positive CD8 + T cells define the response to anti-programmed cell death protein-1 immunotherapy in patients with advanced non-small cell lung cancer

PD-1(+) IFN-gamma(+) subset of CD8(+) T cell in circulation predicts response to anti-PD-1 therapy in NSCLC

PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes

CD161+CD127+CD8+ T Cell Subsets Can Predict the Efficacy of Anti-Pd-1 Immunotherapy in Non-Small Cell Lung Cancer with Diabetes Mellitus

Stromal PD L1–positive regulatory T cells and PD 1–positive CD8 positive T cells define the response of different subsets of non–small cell lung Cancer to PD 1/PD L1 blockade …

Prognostic Value of PD-L1 Expression in Combination with CD8+ TILs Density in Patients with Surgically Resected Non-Small Cell Lung Cancer.

Molecular characterization of clinical responses to PD-1/PD-L1 inhibitors in non-small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD-1 inhibitors in Chinese patients.

Correlation of PD-1 Expression on Peripheral Blood T Cells in Non-Small Cell Lung Cancer and the Efficacy of Immunotherapy

Peripheral CD4 + T cell signatures in predicting the responses to anti-PD-1/PD-L1 monotherapy for Chinese advanced non-small cell lung cancer

Increased CD3+ T cells with a low FOXP3+/CD8+ T cell ratio can predict anti-PD-1 therapeutic response in non-small cell lung cancer patients

Early‐like Differentiation Status of Systemic PD‐1+CD8+ T Cells Predicts PD‐1 Blockade Outcome in Non‐small Cell Lung Cancer

Genomic correlates of the response to first-line PD-1 blockade plus chemotherapy in patients with advanced non-small-cell lung cancer

Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non‐small‐cell lung cancer characterizes the features of response to PD‐1 blockade plus chemotherapy

Intratumoral CD39+CD8+ T Cells Predict Response to Programmed Cell Death Protein-1 or Programmed Death Ligand-1 Blockade in Patients With NSCLC

Regulatory (FoxP3+) T cells and TGF-β predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer

Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8+ T Cells in Non-Small Cell Lung Cancer

Peripheral CD4+ T cells correlate with response and survival in patients with advanced non-small cell lung cancer receiving chemo-immunotherapy

Predictive value of the biomarker of peripheral blood of NSCLC patients responding to anti-PD-1 treatment

T lymphocyte subsets and PD-1 expression on lymphocytes in peripheral blood of patients with non-small cell lung cancer